SECTION 2 | CEACAM5 Precision Therapy – Ten Year Leadership will have to be Designed

Section Summary

Leadership in CEACAM5 will not default to today's first in class — it has to be designed. Three distinct threats face any CEACAM5 franchise, each requiring a different countermove. A diagnostics constraint that is artificially capping the addressable market (addressed by converting diagnostics into a strategic asset, Sections 2.5 and Section 9); category-level fragmentation among ADC competitors (addressed by an unconditional move for incumbents, or niche-locking for new entrants); and platform-level substitution risk from CAR-T or peptide modalities (addressed only by portfolio construction across platforms — no single-category strategy resolves it).

Left to run on its own, the field's default trajectory favors fragmentation — many competitors, each serving a narrow slice of patients — and favors new entrants over incumbents, because permeable IP and a large excluded patient population (currently ~85% of the biologically eligible base, Section 1 for details) leave the door open. Peptide-based diagnostics is the most credible near-term disruption path: it solves the patient-selection bottleneck and the cost-structure problem simultaneously, with a lower-risk initial entry than a therapeutic program.

Section 3 sets out strategic framework and the concrete moves — for incumbents, new entrants, investors, diagnostics companies, and IP support/advisory firms — that determine who holds the category a decade from now. SOC / L1 implications are developed further in Section 10.

Contents

• SECTION 2 | CEACAM5 Precision Therapy – Ten Year Leadership will have to be Designed1
• Section Summary1
• Section 2 : Understanding the Field and Designing Ten Year Leadership2
• 2.1 Scale of the Opportunity2
• 2.2 Current Patient Enrichment: The Sanofi–Agilent CEACAM5 IHC 769 Assay2
• 2.3 The Scale of the White Space2
• 2.4 A Crowded, Multiplayer Field3
• 2.5 Strategy: Converting the Diagnostics Constraint into an Opportunity5
• 2.6 Heading to a Fragmented Market5
• 2.7 Fragmented Markets Favor Change in Leadership5
• 2.8 Modeling Leadership: A Game-Theoretic Framework6
• 2.8.2 The New Entrant's Countermove9
• 2.9 Portfolio Paths to Leadership10
• 2.10 The Investor Perspective: ROI Beyond a Single Asset10
• 2.11 The Third Layer: Platform-Level Competition11
• 2.12 Synthesis and Recommendations11
• Appendix 2.1 — The Credible Unconditional Move13